Impact News +++ TuHURA Biosciences Receives Key U.S. Patent for its Groundbreaking Delta Opioid Receptor (DOR) Antibody Drug... (PR Newswire) +++ TUHURA Aktie +3,24%

INSMED Aktie

>INSMED Aktienkurs

97 EUR -1.8% (TradegateBSX)

Ask: 98 EUR / 100 Stück

Bid: 96 EUR / 100 Stück

Tagesumsatz: 333 Stück

Realtime Kurs von 7:30 bis 22 Uhr!

INSMED Aktie über LYNX handeln

Intraday

1 Jahr

>INSMED Performance

1 Woche: -6,8%

1 Monat: -11,2%

3 Monate: +1,1%

6 Monate: -31,1%

1 Jahr: -23,4%

laufendes Jahr: -35,7%

>INSMED Aktie

Profil:

Insmed Incorporated is a global biopharmaceutical company that develops and commercializes therapies for patients with serious and rare diseases. Its current portfolio includes an approved treatment for Mycobacterium avium complex lung disease, along..
>Volltext..

Insiderhandel:

>INSMED Kennzahlen

Aktien/ Unternehmen:

Analysten:

Bewertung:

Rentabilität:

Managementeffizenz:

>INSMED Peer Group

Gesundheit, Lungen- & Atemwegserkrankungen/ -behandlung

>INSMED Chart & Kurs - NASDAQ

>INSMED News

05.10.26 - 13:42	Insmed CFO Sara Bonstein to step down, reaffirms guidance (SeekingAlpha)
	Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...

05.10.26 - 13:36	Insmed CFO Sara Bonstein To Step Down (AFX)
	WASHINGTON (dpa-AFX) - Insmed Incorporated (INSM), a biopharmaceutical company, said on Monday that Sara Bonstein has decided to step down as chief financial officer. She will continue to serve as......

05.10.26 - 13:03	Insmed Announces CFO Transition (PR Newswire)
	—Sara Bonstein Will Step Down as CFO on October 30 After Nearly Seven Years of Dedicated Leadership— —Company Reaffirms Full-Year 2026 Financial Guidance— —Company Announces Third-Quarter 2026 Financial Results Conference Call to Be Held on Thursday, October 29, 2026— BRIDGEWATER, N.J.,......

22.09.26 - 19:45	FDA Accepts Insmed′s Filing Seeking Label Expansion for Arikayce (Zacks)
	INSM's Arikayce label expansion gets FDA priority review, potentially broadening its use in newly diagnosed MAC lung disease....

21.09.26 - 14:54	Insmed Aktie steigt nach positivem FDA-Bescheid zu Lungenmedikament (Investing.com DE)
	Um den gesamten Artikel unter de.investing.com zu lesen, klicken Sie bitte auf die Überschrift...

21.09.26 - 14:49	FDA-Schnellverfahren für Arikayce treibt Insmed-Aktie an (Investing.com DE)
	Um den gesamten Artikel unter de.investing.com zu lesen, klicken Sie bitte auf die Überschrift...

21.09.26 - 13:03	FDA Grants Priority Review to Insmed′s sNDA for ARIKAYCE® (amikacin liposome inhalation suspension) for Treatment of MAC Lung Disease With PDUFA Target Action Date Set for January 28, 2027 (PR Newswire)
	—sNDA Under Review for Full Approval Is Based on Positive Results From Phase 3b ENCORE Study— —Full Approval Could Bring ARIKAYCE to Patients Earlier in Their Disease Course and Would Fulfill Post-Marketing Requirement From FDA— BRIDGEWATER, N.J., Sept. 21, 2026 /PRNewswire/ -- Insmed......

14.09.26 - 21:48	Insmed auf Morgan Stanley Konferenz: BRINSUPRI-Markteinführung übertrifft Erwartungen und treibt Wachstumskurs (Investing.com DE)
	Um den gesamten Artikel unter de.investing.com zu lesen, klicken Sie bitte auf die Überschrift...

12.09.26 - 07:01	Insiderhandel: Aufsichtsrat verkauft Aktien von Insmed im Wert von 3100000 USD (Insiderkauf)
	Brennan, David R. - Aufsichtsrat - Tag der Transaktion: 2026-09-09...

09.09.26 - 17:30	Insmed hebt auf Konferenz die Umsatzprognose an und stärkt Wachstumsperspektiven (Investing.com DE)
	Um den gesamten Artikel unter de.investing.com zu lesen, klicken Sie bitte auf die Überschrift...

04.09.26 - 13:09	Insmed Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) (PR Newswire)
	BRIDGEWATER, N.J., Sept. 4, 2026 /PRNewswire/ -- Insmed Incorporated (Nasdaq: INSM), a people-first global biopharmaceutical company striving to deliver first- and best-in-class therapies to transform the lives of patients facing serious diseases, today announced the granting of......

03.09.26 - 13:03	Insmed to Present Data Across Its Respiratory Portfolio, Including New Late-Breaking ARIKAYCE® (amikacin liposome inhalation suspension) Results From Phase 3b ENCORE Study at the European Respiratory Society Congress 2026 (PR Newswire)
	—New Data Explore Efficacy and Safety of BRINSUPRI ® (brensocatib) in Patients With Non-Cystic Fibrosis Bronchiectasis (NCFB) and History of Nontuberculous Mycobacterial (NTM) Lung Disease— —New Research Examines Treprostinil Palmitil Inhalation Powder (TPIP) via COMPERA 2.0 Risk......

27.08.26 - 22:00	Liquidia vs. Insmed: Which Pulmonary Stock Has Better Prospects Now? (Zacks)
	Liquidia's Yutrepia is driving strong growth, but Insmed's Brinsupri and broader pipeline could make it the better long-term pick....

26.08.26 - 13:03	Insmed to Present at September 2026 Investor Conferences (PR Newswire)
	BRIDGEWATER, N.J., Aug. 26, 2026 /PRNewswire/ -- Insmed Incorporated (Nasdaq: INSM), a people-first global biopharmaceutical company striving to deliver first- and best-in-class therapies to transform the lives of patients facing serious diseases, today announced that management will......

24.08.26 - 14:01	Insmed′s BRINSUPRI Wins Japan Approval For Treatment Of Non-Cystic Fibrosis Bronchiectasis (AFX)
	WASHINGTON (dpa-AFX) - Monday, Insmed Inc. (INSM) announced that Japan's Ministry of Health, Labour and Welfare has approved BRINSUPRI, or brensocatib 25-mg tablet, for the treatment of non-cystic......

24.08.26 - 13:03	BRINSUPRI® (brensocatib) Approved by Japan′s Ministry of Health, Labour and Welfare for the Treatment of Patients With Non-Cystic Fibrosis Bronchiectasis, a Serious, Chronic Lung Disease (PR Newswire)
	—First-in-Disease and First-in-Class Therapy Approved in Japan for Patients With Non-Cystic Fibrosis Bronchiectasis (NCFB), a Progressive Disease That Can Lead to Permanent Lung Damage— BRIDGEWATER, N.J., Aug. 24, 2026 /PRNewswire/ -- Insmed Incorporated (Nasdaq: INSM), a people-first......

20.08.26 - 02:01	Insiderhandel: Aufsichtsrat verkauft Aktien von Insmed im Wert von 637650 USD (Insiderkauf)
	Sharoky, Melvin Md - Aufsichtsrat - Tag der Transaktion: 2026-08-17...

13.08.26 - 17:24	Insmed (INSM) Q2 2026 Earnings Call Transcript (Fool)
	BRINSUPRI revenue surged to $309.2 million, driving total revenues to $425.5 million....

13.08.26 - 01:01	Insiderhandel: Chief Operating Officer verkauft Aktien von Insmed im Wert von 31964810 USD (Insiderkauf)
	Adsett, Roger - Vorstand - Tag der Transaktion: 2026-08-10...

08.08.26 - 01:01	Insiderhandel: Chief Medical Officer verkauft Aktien von Insmed im Wert von 3494838 USD (Insiderkauf)
	Flammer, Martina M.d. - Vorstand - Tag der Transaktion: 2026-08-06...

>weitere News anzeigen...

>Impressum >Über uns >Datenschutz >Financial Data & Solutions

>Behalte deine Investments mit realtime Kursen & News im Blick. Finde neue spannende Aktien! Registriere Dich und werde Mitglied!

Zitat des Tages: Um einen Graben zu füllen, muß ein Hügel abgetragen werden. - Sprichwort Armenien

Partner: >TradegateBSX Börse | >Dukascopy | >TradingView | >Boersentreff- Partner

Börsentreff auf Facebook |

Börsentreff auf X |

Börsentreff auf Instagram